Work

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?

Year: 2023

Type: article

Abstract: Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging.

Source: Brain

DOI: 10.1093/brain/awad049

Authors: John Hardy, Catherine Mummery

Institutions: UCL Queen Square Institute of Neurology, University College London

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,550